AOD-9604 5mg + CJC-1295 WITHOUT DAC 10mg + Ipamorelin 10mg

The Metabolic Pathway Research Complex combines AOD-9604 5mg with a GH-axis pairing (CJC-1295 Without DAC and Ipamorelin), joining metabolic and GH-axis research categories in a single bundle. AOD-9604 acts through selective beta-3 adrenergic receptor activation, driving lipolytic pathway research independently of the GHR/IGF-1 axis — it does not bind the growth hormone receptor and does not stimulate IGF-1 production, eliminating IGF-1 elevation as a confounding variable. This mechanism is entirely distinct from CJC-1295’s GHRHR pathway and Ipamorelin’s GHSR-1a pathway, allowing all three compounds to function as independent variables within a combined metabolic and GH-axis research protocol.

Sourcing all three compounds as a single-supplier bundle provides batch consistency across the research protocol, with each peptide tested against the same documentation standard by the same independent laboratory.

Every compound in the Metabolic Pathway Research Complex is independently tested by Janoshik laboratory. HPLC purity is confirmed at ≥98% on all three compounds, with LC-MS molecular identity verification. Batch-specific Certificates of Analysis are publicly accessible for AOD-9604, CJC-1295, and Ipamorelin before purchase.

For the CJC-1295 Without DAC component of this bundle, Acetic Acid Water (AA Water) is required for laboratory reconstitution. Do not use standard bacteriostatic water as the intended reconstitution solution for CJC-1295 Without DAC. Other components may have different handling requirements; refer to the relevant product-specific storage and handling information. All three lyophilised peptides may be stored at -20°C, avoiding repeated freeze-thaw cycles.

For complete mechanism detail on each compound, see the AOD-9604, CJC-1295, and Ipamorelin research guides on the Ascend Peptides UK blog, or the metabolic and GH axis research peptides category pages.